{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T18:50:53Z","timestamp":1788288653253,"version":"build-2803163510"},"reference-count":61,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T00:00:00Z","timestamp":1680220800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BLC"],"published-print":{"date-parts":[[2023,3,31]]},"abstract":"<jats:p>Kidney-sparing surgery (KSS) for upper urinary tract urothelial carcinoma (UTUC) is a promising alternative to radical nephroureterectomy, especially for low-risk cases. However, due to the established risk of ipsilateral UTUC recurrence caused by the implantation of floating neoplastic cells after endoscopic resection, adjuvant endocavitary (endoureteral) instillations have been proposed. Instillation therapy may be also used as primary treatment for UTUC. The two most studied drugs that have been evaluated in both the adjuvant and primary setting of endocavitary instillation are mitomycin C and Bacillus Calmette-Guerin. The current paper provides an overview of the endocavitary treatments for UTUC, focusing on methods of administration, novel formulations, oncologic outcomes (in terms of endocavitary recurrence and progression), as well as on complications. In particular, the role of UGN-101 as a primary chemoablative treatment of primary noninvasive, endoscopically unresectable, low-grade, UTUC has been analysed. The drug achieved a complete response rate of 58% after the induction cycle, with a durable response independently of the maintenance cycle. The cumulative experience on the role of UUT instillation therapy appears encouraging; however, no definitive conclusions can be drawn about its therapeutic benefit. Given the current state of the art, any decision to administer adjuvant endoureteral therapy for UTUC should be carefully weighed against the potential adverse events. Nevertheless, newer investigations that improve visualization during ureteroscopy, genomic characterization, novel drugs and innovative strategies of improved drug delivery are under evaluation. The landscape of KSS for the treatment of the UTUC is evolving and seems promising.<\/jats:p>","DOI":"10.3233\/blc-220093","type":"journal-article","created":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T11:09:45Z","timestamp":1675422585000},"page":"15-27","source":"Crossref","is-referenced-by-count":1,"title":["The Role of Local Agents for the Treatment of Localized Upper Tract Urothelial Carcinoma: A Review of the Current Evidence"],"prefix":"10.1177","volume":"9","author":[{"given":"Anastasios D.","family":"Asimakopoulos","sequence":"first","affiliation":[{"name":"Urology Unit, Fondazione PTV Policlinico Tor Vergata, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxim","family":"Kochergin","sequence":"additional","affiliation":[{"name":"Department of Urology and Neurourology, BG Unfallkrankenhaus Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Kl\u00f6cker","sequence":"additional","affiliation":[{"name":"Department of Urology and Pediatric Urology, University Hospital of W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Gakis","sequence":"additional","affiliation":[{"name":"Department of Urology, University Hospital of Halle, Martin-Luther University Halle-Wittenberg, Halle, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/BLC-220093_ref1","doi-asserted-by":"crossref","unstructured":"Siegel RL , Miller KD , Jemal A . Cancer statistics, 2018. CA Cancer J Clin. 2018.","DOI":"10.1891\/9780826121646.0002"},{"issue":"1","key":"10.3233\/BLC-220093_ref2","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.eururo.2020.05.042","article-title":"European association of urology guidelines on upper urinary tract urothelial carcinoma: update","volume":"79","author":"Roupr\u00eat","year":"2021","journal-title":"Eur Urol"},{"issue":"1","key":"10.3233\/BLC-220093_ref3","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1464-410X.2011.10288.x","article-title":"Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscle-invasive and non-organ confined disease in patients with upper tract urothelial carcinoma","volume":"109","author":"Favaretto","year":"2012","journal-title":"BJU Int"},{"key":"10.3233\/BLC-220093_ref4","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.eururo.2016.07.014","article-title":"Oncologic outcomes of kidney-sparing surgery versus radical nephroureterectomy for upper tract urothelial carcinoma: A systematic review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel","volume":"70","author":"Seisen","year":"2016","journal-title":"Eur Urol"},{"key":"10.3233\/BLC-220093_ref5","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nrurol.2015.24","article-title":"Risk-adapted strategy for the kidney sparing management of upper tract tumours","volume":"12","author":"Seisen","year":"2015","journal-title":"Nat Rev Urol"},{"key":"10.3233\/BLC-220093_ref6","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1464-410X.2012.11068.x","article-title":"Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): Systematic review","volume":"110","author":"Cutress","year":"2012","journal-title":"BJU Int"},{"key":"10.3233\/BLC-220093_ref7","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1002\/1097-0142(19800901)46:5<1158::AID-CNCR2820460514>3.0.CO;2-E","article-title":"Urothelial susceptibility to tumor cell implantation: Influence of cauterization","volume":"46","author":"Soloway","year":"1980","journal-title":"Cancer"},{"issue":"3","key":"10.3233\/BLC-220093_ref8","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/S0022-5347(01)66330-4","article-title":"Long-term outcome after percutaneous treatment of transitional cell carcinoma of the renal pelvis","volume":"155","author":"Patel","year":"1996","journal-title":"J Urol"},{"issue":"2","key":"10.3233\/BLC-220093_ref9","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00345-009-0494-x","article-title":"Oncologic control obtained after exclusive flexible ureteroscopic management of upper urinary tract urothelial cell carcinoma","volume":"28","author":"Cornu","year":"2010","journal-title":"World J Urol"},{"issue":"11","key":"10.3233\/BLC-220093_ref10","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1111\/j.1464-410X.2012.11169.x","article-title":"Long-term endoscopic management of upper tract urothelial carcinoma: 20-year single-centre experience","volume":"110","author":"Cutress","year":"2012","journal-title":"BJU Int"},{"issue":"1","key":"10.3233\/BLC-220093_ref11","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/01.ju.0000132128.79974.db","article-title":"Percutaneous nephroscopic management of upper urinary tract transitional cell carcinoma: Recurrence and longterm followup","volume":"172","author":"Palou","year":"2004","journal-title":"J Urol"},{"key":"10.3233\/BLC-220093_ref12","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.urolonc.2019.02.004","article-title":"Endocavitary treatment for upper tract urothelial carcinoma: A meta-analysis of the current literature","volume":"37","author":"Foerster","year":"2019","journal-title":"Urol Oncol"},{"key":"10.3233\/BLC-220093_ref13","unstructured":"Campbell-Walsh Urology. 12th ed. Philadelphia, PA: Elsevier Saunders, 2020."},{"key":"10.3233\/BLC-220093_ref14","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0090-4295(01)01488-1","article-title":"Intravesical instillation of bacille Calmette-Gu\u00e9rin for carcinoma in situ of the urothelium involving the upper urinary tract using vesicoureteral reflux created by a double-pigtail catheter","volume":"59","author":"Irie","year":"2002","journal-title":"Urology"},{"key":"10.3233\/BLC-220093_ref15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s12032-018-1102-y","article-title":"Impact of bacillus Calmette-Guerin therapy of upper urinary tract carcinoma in situ: Comparison of oncological outcomes with radical nephroureterectomy","volume":"35","author":"Horiguchi","year":"2018","journal-title":"Med Oncol"},{"issue":"2","key":"10.3233\/BLC-220093_ref16","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/07357907.2018.1430815","article-title":"Efficacy and tolerability of bacillus calmette-gu\u00e9rintherapy as the first-line therapy for upper urinary tract carcinoma in situ","volume":"36","author":"Tomisaki","year":"2018","journal-title":"Cancer Invest"},{"key":"10.3233\/BLC-220093_ref17","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1097\/01.ju.0000147747.89028.64","article-title":"Assessment of vesicoureteral reflux in patients with self-retaining ureteral stents: Implications for upper urinary tract instillation","volume":"173","author":"Yossepowitch","year":"2005","journal-title":"J Urol"},{"key":"10.3233\/BLC-220093_ref18","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1590\/s1677-5538.ibju.2016.0258","article-title":"Which is best method for instillation of topical therapy to the upper urinary tract? an in vivo porcine study to evaluate three delivery methods","volume":"43","author":"Liu","journal-title":"Int Braz J Urol"},{"key":"10.3233\/BLC-220093_ref19","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.urology.2013.08.048","article-title":"Comparison of 3 upper tract anticarcinogenic agent delivery techniques in an Ex Vivo Porcine Model","volume":"82","author":"Pollard","year":"2013","journal-title":"Urology"},{"issue":"18","key":"10.3233\/BLC-220093_ref20","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1080\/14656566.2020.1805433","article-title":"An evaluation of UGN- 101, a sustained-release hydrogel polymer-based formulation containing mitomycin-C, for the treatment of upper urothelial carcinomas","volume":"21","author":"Porta","year":"2020","journal-title":"Expert Opin Pharmacother"},{"key":"10.3233\/BLC-220093_ref21","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.urology.2016.09.039","article-title":"Sustained-release formulation of Mitomycin C to the upper urinary tract using a thermosensitive polymer: A preclinical study","volume":"99","author":"Donin","year":"2017","journal-title":"Urology"},{"key":"10.3233\/BLC-220093_ref22","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.urolonc.2016.11.019","article-title":"Serial retrograde instillations of sustained release formulation of mitomycin C to the upper urinary tract of the Yorkshire swine using a thermosensitive polymer: Safety and feasibility","volume":"35","author":"Donin","year":"2017","journal-title":"Urol Oncol"},{"key":"10.3233\/BLC-220093_ref23","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S1470-2045(20)30147-9","article-title":"Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): An open-label, single-arm, phase 3 trial","volume":"21","author":"Kleinmann","year":"2020","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.3233\/BLC-220093_ref24","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1097\/JU.0000000000002350","article-title":"Durability of response to primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel: OLYMPUS trial final report","volume":"207","author":"Matin","year":"2022","journal-title":"J Urol"},{"issue":"6","key":"10.3233\/BLC-220093_ref25","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1097\/JU.0000000000002454","article-title":"Antegrade instillation of UGN-101 (mitomycin for pyelocalyceal solution) for low-grade upper tract urothelial carcinoma: Initial clinical experience","volume":"207","author":"Rosen","year":"2022","journal-title":"J Urol"},{"issue":"6","key":"10.3233\/BLC-220093_ref26","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00280-021-04246-w","article-title":"Pharmacokinetics of UGN-101, a mitomycin-containing reverse thermal gel instilled via retrograde catheter for the treatment of low-grade upper tract urothelial carcinoma","volume":"87","author":"Shabsigh","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.3233\/BLC-220093_ref27","unstructured":"Accord Healthcare Inc. Mitomycin injection, powder, lyophilized, for solution. USPI 08\/2-17."},{"issue":"11","key":"10.3233\/BLC-220093_ref28","first-page":"1633","article-title":"Phase I study of oral mitomycin C","volume":"60","author":"Crooke","year":"1976","journal-title":"Cancer Treat Rep"},{"key":"10.3233\/BLC-220093_ref29","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0022-5347(17)47277-6","article-title":"Durable response of a carcinoma in situ of the renal pelvis to topical bacillus Calmette-Guerin","volume":"134","author":"Herr","year":"1985","journal-title":"J Urol"},{"key":"10.3233\/BLC-220093_ref30","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S0022-5347(17)38957-7","article-title":"Percutaneous Bacillus Calmette-Guerin Perfusion of theUpper Urinary Tract for Carcinoma in Situ","volume":"142","author":"Studer","year":"1989","journal-title":"J Urol"},{"key":"10.3233\/BLC-220093_ref31","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0022-5347(17)36117-7","article-title":"Intrarenal bacillus Calmette-Guerin therapy for upper urinary tract carcinoma in situ","volume":"149","author":"Sharpe","year":"1993","journal-title":"J Urol"},{"key":"10.3233\/BLC-220093_ref32","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1046\/j.1464-410X.1996.09559.x","article-title":"Bacillus Calmette- Guerin perfusion therapy for carcinoma in situ of the upper urinary tract","volume":"77","author":"Yokogi","year":"1996","journal-title":"Br J Urol"},{"key":"10.3233\/BLC-220093_ref33","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1046\/j.1464-410x.2000.00610.x","article-title":"Bacillus Calmette-Guerin instillation treatment for carcinoma in situ of the upper urinary tract","volume":"85","author":"Nishino","year":"2000","journal-title":"BJU Int"},{"key":"10.3233\/BLC-220093_ref34","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1159\/000020365","article-title":"Bacillus Calmette- Guerin perfusion therapy for the treatment of transitional cell carcinoma in situ of the upper urinary tract","volume":"38","author":"Nonomura","year":"2000","journal-title":"Eur Urol"},{"key":"10.3233\/BLC-220093_ref35","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1046\/j.1464-410X.2001.02297.x","article-title":"Intrarenal bacillus Calmette-Gu\u00e9rin therapy for carcinoma in situ of the upper urinary tract: Long-term follow-up and natural course in cases of failure","volume":"88","author":"Okubo","year":"2001","journal-title":"BJU Int"},{"key":"10.3233\/BLC-220093_ref36","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1046\/j.1442-2042.2002.00551.x","article-title":"Clinical outcome of bacillus Calmette-Gu\u00e9rin perfusion therapy for carcinoma in situ of the upper urinary tract","volume":"9","author":"Miyake","year":"2002","journal-title":"Int J Urol"},{"key":"10.3233\/BLC-220093_ref37","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.urology.2004.01.046","article-title":"Long-term effects of bacille Calmette-Gu\u00e9rin perfusion therapy for treatment of transitional cell carcinoma in situ of upper urinary tract","volume":"63","author":"Hayashida","year":"2004","journal-title":"Urology"},{"key":"10.3233\/BLC-220093_ref38","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1442-2042.2006.01312.x","article-title":"Long-term outcome of upper urinary tract carcinoma in situ: Effectiveness of nephroureterectomy versus bacillus Calmette-Gu\u00e9rin therapy","volume":"13","author":"Kojima","year":"2006","journal-title":"Int J Urol"},{"key":"10.3233\/BLC-220093_ref39","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1089\/end.2012.0229","article-title":"Outcomes of intrarenal bacillus Calmette-Guerrin\/interferon-2B\u03b1 for biopsy-proven upper-tract carcinoma in situ","volume":"26","author":"Shapiro","year":"2012","journal-title":"J Endourol"},{"key":"10.3233\/BLC-220093_ref40","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/S0022-5347(05)64454-0","article-title":"Long-term experience with bacillus Calmette- Guerin therapy of upper urinary tract transitional cell carcinoma in patients not eligible for surgery","volume":"168","author":"Thalmann","year":"2002","journal-title":"J Urol"},{"key":"10.3233\/BLC-220093_ref41","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.eururo.2011.07.051","article-title":"Antegrade perfusion with bacillus Calmette-Gu\u00e9rin in patients with non-muscle-invasive urothelial carcinoma of the upper urinary tract: Who may benefit?","volume":"60","author":"Giannarini","year":"2011","journal-title":"Eur Urol"},{"key":"10.3233\/BLC-220093_ref42","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0094-0143(21)01586-X","article-title":"Percutaneous treatment of transitional cell carcinoma of the upper urinary tract","volume":"15","author":"Orihuela","year":"1988","journal-title":"Urol Clin North Am"},{"key":"10.3233\/BLC-220093_ref43","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0022-5347(17)37897-7","article-title":"The management of transitional cell carcinoma in solitary renal units","volume":"146","author":"Schoenberg","year":"1991","journal-title":"J Urol"},{"key":"10.3233\/BLC-220093_ref44","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0090-4295(99)80005-3","article-title":"Definitive tumor resection and percutaneous bacille Calmette-Gu\u00e9rin for management of renal pelvic transitional cell carcinoma in solitary kidneys","volume":"45","author":"Vasavada","year":"1995","journal-title":"Urology"},{"key":"10.3233\/BLC-220093_ref45","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0022-5347(01)65854-3","article-title":"Endourological treatment of upper tract urothelial carcinomas: Analysis of a series of 59 tumors","volume":"156","author":"Mart\u00ednez-Pi\u00f1eiro","year":"1996","journal-title":"J Urol"},{"key":"10.3233\/BLC-220093_ref46","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0022-5347(01)64015-1","article-title":"New techniques for the administration of topical adjuvant therapy after endoscopic ablation of upper urinary tract transitional cell carcinoma","volume":"159","author":"Patel","year":"1998","journal-title":"J Urol"},{"key":"10.3233\/BLC-220093_ref47","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0022-5347(01)61765-8","article-title":"13-year experience with percutaneous management of upper tract transitional cell carcinoma","volume":"161","author":"Clark","year":"1999","journal-title":"J Urol"},{"key":"10.3233\/BLC-220093_ref48","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1089\/end.2007.9969","article-title":"Setting a new standard for topical therapy of upper-tract transitional-cell carcinoma: BCG and interferon-\u03b12B","volume":"21","author":"Katz","year":"2007","journal-title":"J Endourol"},{"key":"10.3233\/BLC-220093_ref49","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.urology.2008.06.026","article-title":"A 20-year experience with percutaneous resection of upper tract transitional carcinoma: Is there an oncologic benefit with adjuvant bacillus calmette gu\u00e9rin therapy?","volume":"73","author":"Rastinehad","year":"2009","journal-title":"Urology"},{"issue":"7","key":"10.3233\/BLC-220093_ref50","doi-asserted-by":"crossref","first-page":"e028287","DOI":"10.1136\/bmjopen-2018-028287","article-title":"Protocol for phase I study of pembrolizumab in combination with Bacillus Calmette-Gu\u00e9rin for patients with high-risk nonmuscle invasive bladder cancer","volume":"9","author":"Jamil","year":"2019","journal-title":"BMJ Open"},{"key":"10.3233\/BLC-220093_ref51","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0022-5347(17)35473-3","article-title":"Technique of mitomycin C instillation in the treatment of upper urinary tract urothelial tumors","volume":"150","author":"Eastham","year":"1993","journal-title":"J Urol"},{"key":"10.3233\/BLC-220093_ref52","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1016\/S0022-5347(01)68157-6","article-title":"Adjuvant mitomycin C following endoscopic treatment of upper tract transitional cell carcinoma","volume":"158","author":"Keeley","year":"1997","journal-title":"J Urol"},{"key":"10.3233\/BLC-220093_ref53","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1089\/end.2016.0871","article-title":"Induction and maintenance adjuvant mitomycin C topical therapy for upper tract urothelial carcinoma: Tolerability and intermediate term outcomes","volume":"31","author":"Metcalfe","year":"2017","journal-title":"J Endourol"},{"key":"10.3233\/BLC-220093_ref54","doi-asserted-by":"crossref","first-page":"184","DOI":"10.4103\/0974-7796.115746","article-title":"Mitomycin C instillation following ureterorenoscopic laser ablation of upper urinary tract carcinoma","volume":"5","author":"Aboumarzouk","year":"2013","journal-title":"Urol Ann"},{"key":"10.3233\/BLC-220093_ref55","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1097\/01.ju.0000050242.68745.4d","article-title":"Percutaneous management of renal pelvic urothelial tumors: Long-term followup","volume":"169","author":"Goel","year":"2003","journal-title":"J Urol"},{"issue":"5","key":"10.3233\/BLC-220093_ref56","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1089\/end.2019.0750","article-title":"Adjuvant single-dose upper urinary tract instillation of mitomycin C after therapeutic ureteroscopy for upper tract urothelial carcinoma: A single-centre prospective non-randomized trial","volume":"34","author":"Gallioli","year":"2020","journal-title":"J Endourol"},{"issue":"12","key":"10.3233\/BLC-220093_ref57","doi-asserted-by":"crossref","first-page":"rjab544","DOI":"10.1093\/jscr\/rjab544","article-title":"Systemic BCGosis following intra-renal instillation of BCG: A case report","author":"Schembri Higgans","year":"2021","journal-title":"J Surg Case Rep"},{"issue":"3","key":"10.3233\/BLC-220093_ref58","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1177\/1078155218760160","article-title":"Interstitial pneumonitis and myelosuppression associated to mitomycin C urinary tract instillations: A case report","volume":"25","author":"Rodriguez-Reyes","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"10.3233\/BLC-220093_ref59","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.euf.2018.01.005","article-title":"Genomic profile of urothelial carcinoma of the upper tract from ureteroscopic biopsy: Feasibility and validation using matched radical nephroureterectomy specimens","volume":"5","author":"Bagrodia","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.3233\/BLC-220093_ref60","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ijpharm.2016.08.061","article-title":"Drug-eluting biodegradable ureteral stent: New approach for urothelial tumors of upper urinary tract cancer","volume":"513","author":"Barros","year":"2016","journal-title":"Int J Pharm"},{"key":"10.3233\/BLC-220093_ref61","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.biomaterials.2018.02.035","article-title":"A bilayer swellable drug-eluting ureteric stent: Localized drug delivery to treat urothelial diseases","volume":"165","author":"Lim","year":"2018","journal-title":"Biomaterials"}],"container-title":["Bladder Cancer"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/BLC-220093","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T13:21:15Z","timestamp":1777382475000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/BLC-150352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,31]]},"references-count":61,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.3233\/blc-220093","relation":{},"ISSN":["2352-3727","2352-3735"],"issn-type":[{"value":"2352-3727","type":"print"},{"value":"2352-3735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,31]]}}}